Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2025 Apr 16;31(7):2454. doi: 10.1038/s41591-025-03709-4

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Lindsay B Kilburn 1,✉, Dong-Anh Khuong-Quang 2, Jordan R Hansford 3,4, Daniel Landi 5, Jasper van der Lugt 6, Sarah E S Leary 7, Pablo Hernáiz Driever 8, Simon Bailey 9, Sébastien Perreault 10, Geoffrey McCowage 11, Angela J Waanders 12, David S Ziegler 13,14,15, Olaf Witt 16,17,18,19,20, Patricia A Baxter 21, Hyoung Jin Kang 22, Timothy E Hassall 23, Jung Woo Han 24, Darren Hargrave 25, Andrea T Franson 26, Michal Yalon Oren 27, Helen Toledano 28, Valérie Larouche 29, Cassie Kline 30, Mohamed S Abdelbaki 31, Nada Jabado 32, Nicholas G Gottardo 33, Nicolas U Gerber 34, Nicholas S Whipple 35, Devorah Segal 36, Susan N Chi 37, Liat Oren 38, Enrica E K Tan 39, Sabine Mueller 40, Izzy Cornelio 41, Lisa McLeod 41, Xin Zhao 41, Ashley Walter 41, Daniel Da Costa 41, Peter Manley 41, Samuel C Blackman 41, Roger J Packer 42, Karsten Nysom 43
PMCID: PMC12283413  PMID: 40240838

Correction to: Nature Medicine 10.1038/s41591-023-02668-y, published online 17 November 2023.

In the version of the article initially published, the colors in the Fig. 2 key were switched and have now been amended so that teal represents “Prior BRAFi/MEKi” and orange represents “BRAFi/MEKi-naive”. Additionally, in Fig. 2a, the tenth bar from the left was teal and has now been corrected to orange as the patient was BRAFi/MEKi-naive. These corrections have been made to the HTML and PDF versions of the article.


Articles from Nature Medicine are provided here courtesy of Nature Publishing Group

RESOURCES